Big promises. Big problems. The Affordable Care Act's rocky rollout has exposed deep fault lines in American health care that go beyond malfunctioning website code. From basic questions of coverage to complex federal court cases, many aspects of the sweeping reform remain unsettled. What's gone wrong? Can it be fixed? And where do we go from here? AEI scholars are following the latest developments, offering candid analysis and original research.
Discover Affordable Care Act rollout Content
FILTER BY DATEAll Time
FILTER BY RELEVANCEMost Recent
FILTER BY CONTENT TYPEAll Content Types
The Medicare Trustees issued their annual report on the program's long-term financing last month, and their findings were greeted by the Obama administration as evidence that the Affordable Care Act is working. This is nonsense.
The Obama administration suffered two stinging defeats at the Supreme Court this summer related to the so-called “HHS mandate” — the rule that requires employers to include free contraceptives, sterilization services, and products that can induce early-pregnancy abortions in their health plan offerings to workers.
Would it be economically and ethically feasible to have employers sponsor health insurance for a mixed, high-risk population? My argument is that accounting for deadweight losses tips the scales back in favor of ESI vs. Medicaid.
Earlier this week, I was thinking of writing a column about the lying and duplicity of Obamacare backers who argued that the difference between provisions providing subsidies in states with state-run health exchanges and providing no subsidies in states with federal exchanges resulted from inadvertence or a typographical error.
The Miller-Sanders bill addresses the immediate crisis, but underlying structural defects must be corrected if we are to avoid more problems again soon.
Patient-Centered Outcomes Research Institute (PCORI) never had the resources to fund clinical trials that would create change, and it never had the resources to make grants sizeable enough to perform these trials. PCORI is left with two options, it can either do research on the cheap, or avoid tough medical questions. PCORI has chosen to do both.